KR20230077034A - Composition for Anti-Allergy Using an Extract of Leaves of Ziziphus jujuba - Google Patents

Abstract

The present invention discloses an anti-allergy composition using an extract of Ziziphus jujube leaves which has degranulation inhibitory activity when treated with IgE and antigen (DNP-BSA)-activated mast cell line RBL-2H3 (rat basophilic leukemia).

Description

Composition for Anti-Allergy Using an Extract of Leaves of Ziziphus jujuba}

The present invention relates to a composition for anti-allergy using a jujube tree ( Ziziphus jujuba ) leaf extract.

Allergy is a compound word created by combining the Greek words 'allos' meaning 'change' and 'ergo' meaning 'action' and has the meaning of an adverse reaction in the body. As the etymology suggests, allergy refers to a hypersensitivity reaction such as hives, itching, runny nose, cough, etc. in a specific person due to an abnormality in congenital or acquired immune function to an allergen, a substance that does not show any reaction to normal people. Typical allergens include pollen, drugs, vegetable fibers, bacteria, mold, house dust mites, foods (oval albumin, milk protein, peanuts), dyes, and chemicals. Due to the increase in substances, environmental pollution, reduced immune function due to stress, and changes in dietary habits, these allergic diseases are on the rise worldwide.

Allergic reactions are classified into five types: type I anaphylaxis type, type II cytolytic type, type III immune complex type, type IV cell-mediated type, and type V irritant hypersensitivity reaction type. Allergic reaction is used in the same sense as type I (Roitt I, Brostoff J, Male D. Immunology 6th eds. U.S.A. Mosby. 2001:323-383).

Representative allergic diseases include atopic dermatitis, bronchial asthma, allergic rhinitis, allergic keratitis, and skin urticaria, and mast cells are known as important effector cells for these allergic diseases (Wills-Karp M., et al., Science, 282:2258-61, 1998; Grunig G., et al., Science, 282:2261-2263, 1998). Mast cells are cells that are widely distributed throughout the body, such as skin, respiratory tract, lymphatic ducts, gastrointestinal mucosa, perivascular membranes, and brain (Ishizaka t., et al. J. Immunol. 119:1589, 1997).

Allergic reactions are induced through the activation of intracellular signaling pathways when allergens bind to IgE bound to IgE high-affinity receptors (FcεRI) on the surface of mast cells. Specifically, when an allergen invades a living body, T-helper cells and B cells are sequentially activated to generate IgE. Allergens invading the living body are recognized by antigen-presenting cells, and these antigen-presenting cells differentiate Th0 (T helper cell type 0) into Th2 cells by presenting the allergen. These differentiated Th2 cells secrete cytokines such as IL-4, IL-5, and IL-13, which promote the development of acid leukocytes in the bone marrow to induce acid leukocytes into inflamed tissues, as well as B cells. to induce the production of IgE and IgG1.

The IgE thus produced binds to the high-affinity IgE receptor (FcRIα) on the mast cell membrane, and when allergens such as mites and pollen bind to it and cross-link, the receptor (FcRIα) aggregates. Mast cells are activated by cross-linking and aggregation of the receptor (FcRIα), and the concentration of calcium ions (Ca ⁺⁺ ) in the cytoplasm increases. The increase in calcium ion concentration acts on various types of intracellular regulators, such as cholesterol in the cell membrane or the cytoskeletal system, to move granules to the cell membrane, and at the same time degranulate through vacuolation of the granules, fusion of the granules, and fusion of the granules and the cell membrane. causes When degranulation occurs, preformed mediators stored in mast cells, such as histamine, are released, and at the same time, newly synthesized prostaglandin and leukotriene are secreted together. Chemical transmitters released by degranulation include histamine, serotonin, and leukotrienes, which have vasodilation, enhancement of vascular permeability, contraction of bronchial smooth muscle, and hypersecretion, as well as NCF, which acts as a chemotactic factor for inflammatory cells such as eosinophils and neutrophils. , ECF, PAF, etc. cause allergic reactions (Ennis M, et al., Br J Pharmacol 70:329-334, 1980; Metcalfe DD, et al., Crit Rev Immunol 3:23-74, 1981; Miyajima I, et al., J Clin Invest 99:901-914, 1997; Church MK, et al., J Allergy Clin Immunol 99:155-160, 1997; Jones DA, et al., J Biol Chem 268:9049- 9054, 1993).

Cyclooxygenase (COX) and lipoxygenase (LO) are known to catalyze part of the process of producing prostaglandins and leukotrienes, which are substances that cause allergic symptoms, from arachidonic acid (Sekiya K , et al., Biochem Biophys Acta 713:68-72, 1982)

Therefore, substances that suppress the activation of mast cells, suppress the release of histamine, or inhibit the synthesis of prostaglandins and leukotrienes can be effective treatments for allergies.

Currently, antihistamines (alkylamines, desloratadine, etc.), mast cell stabilizers (cromoglycate, etc.), leukotriene blockers (montelukast, etc.), and anti-IgE antibodies (Omalizumab) are currently used as anti-allergic drugs. However, these drugs are mostly temporary in their effects and often have severe side effects. Therefore, it can be said that it is still necessary to develop a new substance that has a preventive and ameliorative effect on allergic diseases and has a low side effect and a continuous effect. In particular, natural products have the advantage of relatively low toxicity.

The present invention discloses the anti-allergic activity of jujube tree leaf extract.

An object of the present invention is to provide an anti-allergic composition using a jujube leaf extract.

Other objects or specific objects of the present invention will be presented below.

As confirmed in the following examples and experimental examples, the present invention inhibits degranulation when the jujube leaf extract is treated with IgE and antigen (DNP-HSA)-activated mast cell line RBL-2H3 (rat basophilic leukemia) It is completed by checking the .

Considering the foregoing, the present invention can be understood as an anti-allergic composition or an anti-histamine composition comprising a jujube leaf extract as an active ingredient.

In the present specification, "jujube leaf extract" refers to jujube leaf extract to be extracted by water, lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, butanol, etc.), methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate , butyl acetate, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or an extract obtained by leaching using a mixed solvent thereof, carbon dioxide, pentane, etc. It refers to an extract obtained by using a critical extraction solvent or a fraction obtained by fractionating the extract, and the extraction method is any method such as cooling, reflux, heating, ultrasonic radiation, supercritical extraction, etc. method can be applied. In the case of the fractionated extract, after suspending the extract in a specific solvent, the fraction obtained by mixing and standing with a solvent of different polarity, and the crude extract are adsorbed on a column filled with silica gel, etc., and then a hydrophobic solvent, a hydrophilic solvent, or a mixed solvent thereof It is meant to include fractions obtained as a mobile phase. In addition, the meaning of the extract includes a concentrated liquid extract or solid extract from which the extraction solvent is removed by lyophilization, vacuum drying, hot air drying, spray drying, or the like. Preferably, it refers to an extract obtained by using water, ethanol or a mixed solvent thereof as an extraction solvent, and more preferably an extract obtained by using a mixed solvent of water and ethanol as an extraction solvent.

In addition, in the present specification, "active ingredient" means a component that exhibits the desired activity alone or can exhibit activity in combination with a carrier having no activity itself.

Also, in the present specification, "anti-allergy" is meant to include improvement (relief of symptoms), treatment, and prevention (inhibition or delay of onset) of allergic diseases defined below.

In addition, in the present specification, "allergic disease" refers to pathological symptoms caused by allergic reactions mediated by mast cell activation, such as mast cell degranulation, and such allergic diseases include atopic dermatitis, asthma , allergic rhinitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, and allergic keratitis.

The anti-allergic composition of the present invention may contain the active ingredient in an arbitrary amount (effective amount) as long as it can exhibit an activity to improve the allergic disease intended for treatment according to the purpose of use, formulation, combination, etc. It will be determined within the range of 0.001% to 15% by weight based on the total weight of the composition. Here, "effective amount" means that when the composition of the present invention is administered to a mammal, preferably a human to which it is applied, during the administration period according to the advice of medical experts, the intended medical and pharmacological effects such as the improvement of allergic diseases are exhibited. It refers to the amount of the active ingredient included in the composition of the present invention. Such an effective amount can be determined empirically within the ordinary skill of the skilled artisan.

In addition to the active ingredients, the anti-allergic composition of the present invention may further include any compounds or natural extracts whose safety has already been verified and are known to have anti-allergic activity in order to increase or enhance anti-allergic activity.

Specifically, such compounds or extracts include Enterococcus faecalis heat-treated dried powder, which has been individually recognized for its 'hypersensitive immune response' function according to the "Health Functional Food Act", complexes such as guava leaf extract, Complexes such as picaopreto powder, PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol), L. sakei Probio 65, individually recognized for its 'improving sensitive skin condition' function, and gamma-linolenic acid-containing maintenance , fruit and vegetable-derived lactic acid bacteria ( L.plantarum CJLP133), probiotics ATP, and the like.

One or more of these compounds or natural extracts may be included in the anti-allergic composition of the present invention together with the active ingredient.

In a specific aspect, the anti-allergic composition of the present invention can be regarded as a food composition. When the composition of the present invention is understood as a food composition, its use can be understood as suppression of allergic hypersensitivity reaction or allergic skin hypersensitivity reaction.

The food composition of the present invention can be prepared in any form, for example, beverages such as tea, juice, carbonated beverages, and ionic beverages, processed oils such as milk and yogurt, chewing gum, rice cakes, traditional Korean snacks, bread, snacks, noodles, etc. It can be manufactured into health functional food preparations such as foods, tablets, capsules, pills, granules, liquid, powder, flakes, pastes, syrups, gels, jellies, and bars.

In addition, the food composition of the present invention may take any product classification as long as it conforms to the enforcement regulations at the time of manufacture and distribution in legal and functional classification. For example, health functional food according to the Korean 「Health Functional Food Act」, or snacks, legumes, teas, beverages according to each food type according to the Food Code (MFDS notification 「Food Standards and Specifications」) of the Korea 「Food Sanitation Act」 , special purpose foods, etc.

The food composition of the present invention may include food additives in addition to the active ingredient. Food additives may generally be understood as substances that are added to, mixed with, or infiltrated into food in manufacturing, processing, or preserving food. Since food is consumed daily and for a long period of time, its safety must be guaranteed. According to the Food Additives Code under the laws of each country governing the manufacture and distribution of food (in Korea, it is the 「Food Sanitation Act」), safety-guaranteed food additives are limitedly regulated in terms of ingredients or functions. In the Korean Food Additives Codex (MFDS notification 「Standards and Specifications for Food Additives」), food additives are classified into chemical synthetic products, natural additives and mixed preparations in terms of ingredients and are regulated. It is divided into additives, preservatives, emulsifiers, acidulants, and thickeners.

Sweeteners are used to impart appropriate sweetness to foods, and both natural and synthetic sweeteners can be used in the composition of the present invention. Preferably, a natural sweetener is used, and examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.

Flavors may be used to improve taste or aroma, and both natural and synthetic flavors may be used. Preferably, it is the case of using a natural one. In case of using natural ones, in addition to flavor, the purpose of enhancing nutrition can also be combined. As a natural flavoring agent, it may be obtained from apples, lemons, tangerines, grapes, strawberries, peaches, etc., or obtained from green tea leaves, roundworms, bamboo leaves, cinnamon, chrysanthemum leaves, jasmine, and the like. In addition, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, ginkgo, etc. can be used. Natural flavors can be liquid concentrates or solid extracts. In some cases, synthetic flavors may be used, and synthetic flavors may include esters, alcohols, aldehydes, terpenes, and the like.

As preservatives, sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. may be used, and as emulsifiers, acacia gum, carboxymethylcellulose, xanthan gum, pectin and the like, and examples of the acidulant include acid salt, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, and the like. Acidulants may be added to the food composition to have an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to improving taste.

As the thickening agent, a suspending agent, a sedimentation agent, a gel forming agent, a swelling agent, and the like may be used.

In addition to the food additives described above, the food composition of the present invention may include physiologically active substances or minerals known in the art and whose stability is guaranteed as food additives for the purpose of supplementing or reinforcing functionality and nutrition.

Examples of such physiologically active substances include catechins contained in green tea, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, dibenzoylthiamine, and the like. Examples of minerals include calcium preparations such as calcium citrate and magnesium stearate. magnesium preparations such as the like, iron preparations such as iron citrate, chromium chloride, potassium iodine, selenium, germanium, vanadium, zinc, and the like.

The food composition of the present invention may include the above-mentioned food additives in an appropriate amount to achieve the purpose of addition according to the type of product.

Regarding other food additives that may be included in the food composition of the present invention, reference may be made to national food codes or food additive codes.

The composition of the present invention can be understood as a pharmaceutical composition in another specific aspect.

The pharmaceutical composition of the present invention may be formulated into an oral formulation or a parenteral formulation according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient. The route of administration herein may be any appropriate route including topical route, oral route, intravenous route, intramuscular route, and direct absorption through mucosal tissue, and two or more routes may be used in combination. An example of a combination of two or more routes is a case in which two or more formulations of drugs are combined according to the route of administration, for example, one drug is firstly administered intravenously and the other drug is secondly administered through a topical route.

Pharmaceutically acceptable carriers are well known in the art depending on the route of administration or dosage form, and specifically, reference may be made to the pharmacopoeia of each country including the "Korean Pharmacopoeia".

When the pharmaceutical composition of the present invention is prepared as an oral dosage form, powder, granule, tablet, pill, dragee, capsule, liquid, gel, syrup, suspension, wafer according to a method known in the art together with a suitable carrier. It can be prepared in formulations such as Examples of suitable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, starches such as corn starch, potato starch, and wheat starch, cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, Celluloses such as hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil, ethanol, glycerol etc. can be mentioned. When formulated, appropriate binders, lubricants, disintegrants, coloring agents, diluents, etc. may be included as needed. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, glucose, corn sweetener, sodium alginate, polyethylene glycol, wax, and the like, and sodium oleate as a lubricant , sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, magnesium salts and calcium salts thereof, polyethylene glycol, etc. as disintegrants, starch, methyl cellulose, agar, bentonite, xanthan gum, starch, alginic acid or its sodium salt, and the like. Examples of the diluent include lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine.

When the pharmaceutical composition of the present invention is prepared as a parenteral formulation, it may be formulated in the form of an injection, transdermal administration, nasal inhalation, and suppository along with a suitable carrier according to a method known in the art. When formulated as an injection, an aqueous isotonic solution or suspension may be used as a suitable carrier, and specifically, an isotonic solution such as phosphate buffered saline (PBS) containing triethanolamine, sterile water for injection, or 5% dextrose may be used. . When formulated as a transdermal formulation, it may be formulated in the form of ointments, creams, lotions, gels, external solutions, pastas, liniments, air rolls, and the like. In the case of nasal inhalation, it can be formulated in the form of an aerosol spray using a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc., and when formulated as a suppository, the carrier is Witepsol ( witepsol), tween 61, polyethylene glycols, cacao fat, laurin fat, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, sorbitan fatty acid esters, and the like can be used.

Regarding the specific formulation of the pharmaceutical composition, it is known in the art, and for example, reference may be made to Remington's Pharmaceutical Sciences (19th ed., 1995) and the like. These documents are considered as part of this specification.

The preferred dosage of the pharmaceutical composition of the present invention is in the range of 0.001 mg/kg to 10 g/kg per day, preferably 0.001 mg/kg to 1 g, depending on the patient's condition, weight, sex, age, severity of the patient, and route of administration. /kg range. Administration can be done once a day or divided into several times. These dosages should not be construed as limiting the scope of the present invention in any respect.

In another specific aspect, the composition of the present invention can be identified as a cosmetic composition. When the composition of the present invention is understood as a cosmetic composition, its use can be understood as the use of allergic skin trouble suppression, allergic skin irritation relief, and the like.

Even when the composition of the present invention is identified as a cosmetic composition, the cosmetic composition may be classified as an arbitrary product in terms of its use and law, and specifically, functional cosmetics and non-functional cosmetics with uses such as improving skin troubles and atopic dermatitis. It may be a general cosmetic or the like. In product form, it may take any product form, specifically, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax It may take the form of a product such as foundation or spray. In a specific product form, it may be a softening lotion, nutrient lotion, nutrient cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, or powder formulation.

The cosmetic composition of the present invention may include, in addition to the active ingredient, components commonly used in cosmetic compositions, for example, stabilizers, solubilizers, surfactants, vitamins, conventional adjuvants such as pigments and fragrances, and carriers.

When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, specifically water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol, fatty acid esters of sorbitan, and the like may be used.

When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar, and the like can be used.

When the formulation of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

The cosmetic composition of the present invention may be prepared according to a method for preparing a cosmetic composition conventionally performed in the art, except for including the active ingredient exhibiting anti-allergic activity.

As described above, according to the present invention, an anti-allergic composition using a jujube leaf extract can be provided.

The anti-allergic composition of the present invention can be commercialized as food, cosmetics, medicine, etc. for use in improving allergic diseases.

1 is a result showing that the cytotoxicity of the jujube tree leaf extract is not shown.
Figure 2 is a result showing the degranulation inhibitory activity of the jujube tree leaf extract.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these Examples and Experimental Examples.

< Example > Manufacture of jujube leaf extract

Dried jujube tree ( Ziziphus jujuba var. inemmis ) After adding 100 g of 10-fold weight of 70% ethanol aqueous solution to 100 g of ground leaf, leaving it at room temperature for 24 hours, extracting twice, filtering, and then concentrating the filtrate under reduced pressure and freeze-drying to obtain 20.7 g of solid jujube leaf extract. did

< Experimental example > Cell Reading Lab anti-allergy active experiment

<Experimental Example 1> Cytotoxicity test

Mast cells (RBL-2H3) were cultured in DMEM (Gibco, 11995) medium supplemented with 10% FBS (Fetal bovine serum; Gibco, 16000) and 1% penicillin-streptomycin (Sigma, P4458) at 37°C and 5% It was cultured in a CO2 cell incubator. Thereafter, the HaCaT cells were dispensed in a 96-well plate at the number of 1×10 ⁴ cells/well, cultured for 24 hours, and then, extracts were added to the medium as samples according to concentration. The cells to which the sample was added were cultured for 24 hours. In order to confirm cytotoxicity, 20 μl of MTS solution (CellTiter 96® Aqueous One Solution Cell Proliferation Assay; Promega, G3581) was added to the cells to which the sample was added, and then incubated at 37 ° C until the OD value was 1.0 to 1.5. Cultured in % CO2 cell culture medium. Absorbance was measured at 485 nm using a multifunction plate reader (Envision; PerkinElmer, USA).

The cytotoxicity test results are shown in FIG. 1 . Referring to Figure 1, it can be seen that the jujube leaf extract does not show any particular cytotoxicity.

<Experimental Example 2> Anti-allergic activity test - β-hexosaminidase assay

Measurement of degranulation from RBL-2H3 cells was investigated by measuring the activity of inhibiting the secretion of β-hexosaminidase, which is a biomarker of degranulation. RBL-2H3 cells were plated at 1×10 ⁴ cells/well in a 96-well plate by adding dinitropheny-immunoglobulin E (DNP-IgE, 20 ng/mL) to MEM medium containing 15% FBS and 1% penicillin-streptomycine. After dividing, it was cultured for 24 hours in a 37℃, 5% CO ₂ incubator. Each cell was washed twice with Siraganian buffer (119 mM NaCl, 5 mM KCl, 5.6 mM glucose, 0.4 mM MgCl ₂ , 25 mM PIPES, 1 mM CaCl ₂ , 0.1% BSA, pH 7.2), and then the samples were mixed in Siraganian buffer. Diluted by stars (0, 6.25, 12.5, 25, 50, 100, 200 μg/mL), treated with cells, and reacted in a 37°C, 5% CO ₂ incubator for 1 hour. Thereafter, dinitrophenyl-human serum albumin (DNP-HSA, 200 ng/mL) was added, reacted in a 37°C, 5% CO ₂ incubator for 30 minutes, and left on ice for 5 minutes to terminate the reaction. Transfer 20 μL of the supernatant to a new 96-well plate, lyse the cells with 0.1% Triton X-100 to measure hexosaminidase remaining in the cells, and transfer 20 μL to another new 96-well plate. Add 20 μL of substrate buffer (1 mM 4-p-nitrophenyl-N-acetyl-β-D-glucosaminide in 0.1 M citrate buffer, pH 4.5) to the supernatant and cell lysate, incubate at 37°C for 1 hour, and then stop. Solution (0.1 M NaHCO ₃ /Na ₂ CO ₃ ) was added to terminate the reaction by adding 160 μL, and absorbance was measured at 405 nm using a multilabel plate reader (EnVision ^TM , PerkinElmer). In the degranulation calculation method, the amount of supernatant relative to the total amount of hesoxaminidase was expressed as % release, and then the DNP-HSA untreated group was 100% inhibition and the DNP-HSA treated group (AG) was 0% inhibition. The degranulation effect was expressed as % inhibition. As a positive control, R406, an IgE inhibitor, was used.

The results are shown in FIG. 2. The samples of the examples inhibited degranulation in a concentration-dependent manner, and showed an inhibitory activity of close to 90% at the highest treatment concentration of 100 μg/m.

Claims (7)

An anti-allergic composition comprising a jujube leaf extract as an active ingredient.
According to claim 1,
The jujube leaf extract is an anti-allergic composition, characterized in that the extract obtained by extraction with water, ethanol or a mixed solvent thereof.
According to claim 1,
The anti-allergy means improvement, treatment, suppression or delay of the onset of allergic diseases,
The allergic disease includes atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, and allergic contact dermatitis. ), and an anti-allergic composition, characterized in that one selected from the group consisting of allergic keratitis.
According to any one of claims 1 to 3,
The composition is an anti-allergic composition, characterized in that the pharmaceutical composition.
According to any one of claims 1 to 3,
The composition is an anti-allergic composition, characterized in that the food composition.
According to any one of claims 1 to 3,
The composition is an anti-allergic composition, characterized in that the cosmetic composition.
An antihistamine composition comprising jujube leaf extract as an active ingredient.

Images